Microdosing LSD Analogues for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Microdosing LSD Analogues for Health & Longevity

Created on 08/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Very small, repeated doses of compounds the body converts into LSD. Controlled work shows longer sleep after a dose and better mood while the drug is active, nothing lasting once dosing stops, and a small drop in mental control. Inexpensive, untested, unregulated. (Full Review)

Protocol

Dose range
5–20 µg of LSD base
10 µg is the perceptual threshold; conversion unmeasured.
The Fadiman schedule (one day on, two days off)
Days 1, 4, 7
The better-validated schedule; used in controlled trials.
Best time of day
Morning, before 10:00
Every controlled trial dosed in the morning; evening dosing untested.
Time to effect
Sleep duration
Night after each dose
Device-measured increase of about 24 minutes.
Mood and energy
About 1.1 hours
Effects end at about 5.1 hours; evidence conflicted.
Assessment period
4–6 weeks
Ten to fourteen dosing days; no cumulative effect detected.

Benefits

Contraindications
  • MAO inhibitors (phenelzine), linezolid
  • Lithium
  • Ergot and 5-HT2B drugs (ergotamine), chronic use
  • Personal or first-degree family history of bipolar I/II, schizophrenia, psychosis
  • Valvular disease of any grade, including trivial regurgitation; pulmonary hypertension
  • Uncontrolled hypertension (140/90 mmHg or above), unstable coronary disease, myocardial infarction under 90 days, stroke or transient ischaemic attack under 12 months
  • Seizure disorder
  • Hepatic impairment, Child-Pugh Class B or C
  • Pregnancy, conception attempts or breastfeeding
  • Safety-critical occupations
    •
Key Interactions
  • Serotonin and serotonin-noradrenaline reuptake inhibitors (fluoxetine, venlafaxine)
  • Tricyclic antidepressants (amitriptyline)
  • CYP2D6 inhibitors (paroxetine, bupropion)
  • Antihypertensives (amlodipine, metoprolol)
  • Over-the-counter medications (dextromethorphan)
  • Serotonergic supplements (5-HTP, L-Tryptophan)
  • Stimulant supplements (caffeine, yohimbine)
  • Supplements that alter clearance (grapefruit)
  • Other interventions (full-dose sessions, alcohol)
    •

Risk & Side Effects

  • High: Treatment-emergent anxiety; acute blood pressure elevation; impaired cognitive control
    •
  • Medium: Unknown compound identity; chemical instability; expectancy-driven benefit; legal exposure
    •
  • Low: Tolerance; sleep-onset disruption with late dosing; headache, nausea, gastrointestinal discomfort
    •
  • Speculative: Valvular heart disease; compound-specific cardiac and genotoxic signals; persisting perception disorder; hypomania or mania
    •

Monitoring

Marker Target Why
Echocardiogram No regurgitation beyond trivial Main theoretical long-term risk
Blood pressure (home series) Under 120/80; on-dose rise <10 Individual vascular response
Resting heart rate 50–70 bpm; on-dose shift <5 Adrenergic component of response
hs-CRP Below 1.0 mg/L Tests the anti-inflammatory rationale
ALT and AST ALT <25 (m), 20 (w); AST <25 Liver performs clearance
Complete blood count Within reference range Predicted haematological signal
ECG (12-lead), QTc Below 440 ms (men), 460 (women) Predicted cardiac ion-channel effect
Fasting glucose and HbA1c 75–85 mg/dL; HbA1c 4.8–5.2% Metabolic control undisturbed
Thyroid panel (TSH, free T3/T4) TSH 1.0–2.0; fT3/fT4 upper half Confounder for mood and sleep

Cadence: Blood pressure and symptoms daily for four weeks, then weekly. Blood work at 3 months, then every 6–12 months. Echocardiography at 12 months, then every 12–24 months.

Qualitative Assessment

  • Sleep duration and quality: Wearable sleep time, dosing versus non-dosing nights
  • Mood, energy and irritability: Brief daily ratings on a fixed scale
  • Anxiety: Tracked separately; a sustained rise is a signal to reduce or stop
  • Cognitive control in daily work: Errors of inattention and distraction on dosing days
  • Sense of connectedness and engagement: Improvements on dosing days
  • Success definition: A direction-specific on-dose difference that survives self-blinding
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.